EXE vs. WELL, DR, SIA, DNTL, GUD, ACB, FRX, WEED, KSI, and VHI
Should you be buying Extendicare stock or one of its competitors? The main competitors of Extendicare include WELL Health Technologies (WELL), Medical Facilities (DR), Sienna Senior Living (SIA), dentalcorp (DNTL), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Fennec Pharmaceuticals (FRX), Canopy Growth (WEED), kneat.com (KSI), and Vitalhub (VHI). These companies are all part of the "medical" sector.
Extendicare (TSE:EXE) and WELL Health Technologies (TSE:WELL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Extendicare has a net margin of 2.60% compared to WELL Health Technologies' net margin of 0.01%. Extendicare's return on equity of 36.03% beat WELL Health Technologies' return on equity.
In the previous week, WELL Health Technologies had 10 more articles in the media than Extendicare. MarketBeat recorded 10 mentions for WELL Health Technologies and 0 mentions for Extendicare. WELL Health Technologies' average media sentiment score of 0.29 beat Extendicare's score of 0.00 indicating that WELL Health Technologies is being referred to more favorably in the news media.
21.2% of Extendicare shares are owned by institutional investors. Comparatively, 4.8% of WELL Health Technologies shares are owned by institutional investors. 13.6% of Extendicare shares are owned by insiders. Comparatively, 9.6% of WELL Health Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Extendicare currently has a consensus price target of C$7.88, indicating a potential upside of 7.00%. WELL Health Technologies has a consensus price target of C$7.39, indicating a potential upside of 104.11%. Given WELL Health Technologies' stronger consensus rating and higher possible upside, analysts plainly believe WELL Health Technologies is more favorable than Extendicare.
Extendicare received 112 more outperform votes than WELL Health Technologies when rated by MarketBeat users. However, 66.10% of users gave WELL Health Technologies an outperform vote while only 49.19% of users gave Extendicare an outperform vote.
Extendicare has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, WELL Health Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
Extendicare has higher revenue and earnings than WELL Health Technologies.
Summary
Extendicare beats WELL Health Technologies on 9 of the 17 factors compared between the two stocks.
Get Extendicare News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Extendicare Competitors List
Related Companies and Tools
